43 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Aug 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
4:06pm
, business plans, business strategy and clinical trials; Lyell’s advancement of its pipeline and its research, development and clinical capabilities
424B5
LYEL
Lyell Immunopharma, Inc.
6 May 24
Prospectus supplement for primary offering
8:12am
ability to pursue our growth strategy and adversely affect the market price of our common stock.
It is not possible to predict the aggregate proceeds … , including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
6 May 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
8:03am
regarding: Lyell’s anticipated progress, business plans, business strategy and clinical trials; Lyell’s advancement of its pipeline and its research
S-3
l19zg2ji ra7rz
28 Feb 24
Shelf registration
7:49pm
8-K
EX-99.1
gc6jsbv
28 Feb 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
4:07pm
8-K
EX-99.1
g1akn1un zt8jxfz3k9l
7 Nov 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
4:08pm
8-K
EX-99.1
b7tr mawcv4pa
11 Sep 23
Regulation FD Disclosure
9:16am
8-K
EX-99.1
7pp9bfn1 z3rsi
8 Aug 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
4:10pm
8-K
EX-99.1
1bwl1pnei5zka1qb
4 May 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4:11pm
8-K
EX-99.1
ec6jdmovddkx2 jfl
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
EX-99.1
ye9xdbhzsifie8fti
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm